SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
128.80    4.60 (3.70%)
Bid:
128.20
Ask:
129.60
Spread: 1.40 (1.092%)
Market Cap: £536.34m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Pre-Close Trading Statement

25 Jul 2018 07:00

RNS Number : 6057V
James Halstead PLC
25 July 2018
 

25 July 2018

 

 

Pre-Close Trading Statement

 

 

James Halstead plc, the commercial flooring manufacturer and distributor, is providing the following trading update ahead of its final results for the year ended 30 June 2018.

 

We are pleased to report that sales for the year were ahead of the comparative year. This represents a creditable performance in still difficult trading conditions. It is particularly pleasing to report that our UK turnover is 3% ahead of the prior year in a market that seems to be quite robust despite the well reported spending cuts and high street retailer issues.

 

In the Chairman's interim statement, announced on 29 March 2018, it was noted that adverse price pressure on raw materials was holding back the benefits of export currency gains. This continued in the second half year but was ameliorated by increased sales. The Chairman, in that statement, noted that a German competitor had entered administration and at that time we decided to undertake our largest ever re-vamp of our homogenous flooring ranges with the launch of "Palettone."

 

Palettone is a premium homogenous sheet vinyl collection, launched in May 2018. It is the largest new product development by any manufacturer in this core product area in many years. It offers a collection of 50 colours optimised for our global market and is presented in a unique, innovative sample package with full customer support from specification to installation. The feedback we have received on the collection since launch has been exceptional.

 

The costs of development trials, sampling, marketing material and related costs have been around £2 million and the product has just been launched into the global market place. The timescale that our production and marketing staff worked to was ambitious and we are delighted with the successful launch.

 

In line with best practice, we shall expense these costs rather than amortise or construct an adjustment to "underlying" earnings.

 

Consequently we are pleased to anticipate, once again, reporting record turnover and expect profits for the year to 30 June 2018 will be in line with last year.

 

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 

 

 

Enquiries:

 

 

Mark Halstead, Chief Executive

 

Gordon Oliver, Finance Director

Telephone: 0161 767 2500

 

 

Nick Lyon - Hudson Sandler

Telephone: 020 7796 4133

 

 

Ben Thorne

Dominic Morley - Panmure Gordon

(Nominated advisor and broker)

 

Telephone: 020 7886 2500

 

Chris Hardie - Arden Partners

Telephone: 020 7614 5900

(Broker)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTBZLFLVDFEBBX
Date   Source Headline
25th Jan 20107:00 amRNSPre-close Trading Statement
4th Jan 20107:00 amRNSBlocklisting Interim Review
31st Dec 20097:00 amRNSTotal Voting Rights
18th Dec 20094:00 pmRNSAnnual Report and Accounts
14th Dec 200911:30 amRNSDirector's shareholding
10th Dec 20093:00 pmRNSDirector's shareholding
7th Dec 20091:50 pmRNSDirector's shareholding
4th Dec 20091:00 pmRNSDividend Declaration
4th Dec 20097:00 amRNSAGM Statement
12th Oct 200912:00 pmRNSDirector/PDMR Shareholding
29th Sep 20097:00 amRNSPreliminary Results
17th Sep 200911:37 amRNSNotice of Preliminary Results
29th Jul 20097:00 amRNSPre-Close Trading Update
1st Jul 200912:30 pmRNSBlocklisting Interim Review
30th Mar 20094:45 pmRNSDividend Declaration - Correction
30th Mar 20097:00 amRNSInterim Results
17th Mar 20093:12 pmRNSNotice of Results
26th Feb 20098:00 amRNSBlocklisting Interim Review
28th Jan 20097:00 amRNSPre-close Trading Statement
22nd Dec 200812:30 pmRNSAnnual Report and Accounts
10th Dec 20087:00 amRNSAGM Statement
8th Oct 200812:00 pmRNSDirector/PDMR Shareholding
6th Oct 20085:00 pmRNSDirector/PDMR Shareholding
30th Sep 20085:08 pmRNSDirectors' Dealings
30th Sep 20087:00 amRNSFinal Results
24th Sep 20087:00 amRNSExecutive Board Appointment
19th Sep 20084:50 pmRNSSecond Price Monitoring Extn
19th Sep 20084:35 pmRNSPrice Monitoring Extension
16th Sep 200810:00 amRNSNotice of Results
4th Sep 20087:00 amRNSNotice of Results
31st Jul 20087:00 amRNSTotal Voting Rights
3rd Jul 20081:00 pmRNSBlocklisting Interim Review
1st Jul 20087:00 amRNSTrading Statement
11th Jun 20081:00 pmRNSAdditional Listing
30th May 200810:58 amRNSTotal Voting Rights
14th May 20087:00 amRNSDirector/PDMR Shareholding
31st Mar 20087:00 amRNSInterim Results
1st Feb 20084:50 pmRNSTotal Voting Rights
31st Jan 20083:49 pmRNSAdditional Listing
30th Jan 20082:16 pmRNSDirector/PDMR Shareholding
28th Jan 20087:00 amRNSPre-close Trading Update
23rd Jan 20084:31 pmRNSBlock Listing Returns
15th Jan 20081:11 pmRNSDirector/PDMR Shareholding
7th Jan 200812:43 pmRNSDirector/PDMR Shareholding
7th Dec 20077:01 amRNSAGM Statement
15th Nov 200710:56 amRNSAnnual Report and Accounts
1st Oct 20077:01 amRNSFinal Results
10th Sep 20079:38 amRNSNotice of Results
31st Aug 20073:33 pmRNSTotal Voting Rights
23rd Aug 20071:21 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.